These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11522229)

  • 1. The biology of natural killer cells and implications for therapy of human disease.
    Chiorean EG; Miller JS
    J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cellular therapy with natural killer cells.
    Klingemann H; Boissel L
    Horm Metab Res; 2008 Feb; 40(2):122-5. PubMed ID: 18283630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges of cancer therapy with natural killer cells.
    Klingemann H
    Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
    Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
    Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products.
    Itescu S; Artrip JH; Kwiatkowski PA; Wang SF; Minanov OP; Morgenthau AS; Michler RE
    Ann Transplant; 1997; 2(1):14-20. PubMed ID: 9869836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusions of allogeneic natural killer cells as cancer therapy.
    Leung W
    Clin Cancer Res; 2014 Jul; 20(13):3390-400. PubMed ID: 24987108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cells: the journey from puzzles in biology to treatment of cancer.
    Bodduluru LN; Kasala ER; Madhana RM; Sriram CS
    Cancer Lett; 2015 Feb; 357(2):454-67. PubMed ID: 25511743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
    Tallerico R; Todaro M; Di Franco S; Maccalli C; Garofalo C; Sottile R; Palmieri C; Tirinato L; Pangigadde PN; La Rocca R; Mandelboim O; Stassi G; Di Fabrizio E; Parmiani G; Moretta A; Dieli F; Kärre K; Carbone E
    J Immunol; 2013 Mar; 190(5):2381-90. PubMed ID: 23345327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer.
    Ruggeri L; Mancusi A; Capanni M; Martelli MF; Velardi A
    Curr Opin Immunol; 2005 Apr; 17(2):211-7. PubMed ID: 15766683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
    Tonn T; Becker S; Esser R; Schwabe D; Seifried E
    J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
    Karlhofer FM; Ribaudo RK; Yokoyama WM
    Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells for osteosarcoma.
    Tarek N; Lee DA
    Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of human and mouse natural killer tumor recognition using retroviral antisense in primary natural killer cells: involvement with MHC class I killer cell inhibitory receptors.
    Ortaldo JR; Mason AT; Mason LH; Winkler-Pickett RT; Gosselin P; Anderson SK
    J Immunol; 1997 Feb; 158(3):1262-7. PubMed ID: 9013968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.